• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对杜兴氏肌营养不良症患者通过6分钟步行距离测量的动态功能自然史轨迹进行分类。

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.

作者信息

Mercuri Eugenio, Signorovitch James Edward, Swallow Elyse, Song Jinlin, Ward Susan J

机构信息

Paediatric Neurology Unit, Catholic University, Rome, Italy.

Analysis Group, Inc., 111 Huntington Ave, 10th Floor, Boston, MA, USA; The TAP Collaboration, One Broadway, 14th Floor, Cambridge, MA, USA.

出版信息

Neuromuscul Disord. 2016 Sep;26(9):576-83. doi: 10.1016/j.nmd.2016.05.016. Epub 2016 May 27.

DOI:10.1016/j.nmd.2016.05.016
PMID:27423700
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5026045/
Abstract

High variability in patients' changes in 6 minute walk distance (6MWD) over time has complicated clinical trials of treatment efficacy in Duchenne muscular dystrophy (DMD). We assessed whether boys with DMD could be grouped into classes that shared similar ambulatory function trajectories as measured by 6MWD. Ambulatory boys aged 5 years or older with genetically confirmed DMD who were enrolled in a natural history study at 11 care centers throughout Italy were included. For each boy, standardized assessments of 6MWD were available at annual intervals spanning 3 years. Trajectories of 6MWD vs. age and trajectories of 6MWD vs. time from enrollment were examined using latent class analysis. A total of 96 boys were included. At enrollment, the mean age was 8.3 years (mean 6MWD: 374 meters). After accounting for age, baseline 6MWD, and steroid use, four latent trajectory classes were identified as explaining 3-year 6MWD outcomes significantly better than a single average trajectory. Patient trajectories of 6MWD change from enrollment were categorized as having fast decline (n = 25), moderate decline (n = 19), stable function (n = 37), and improving function (n = 15) during the 3-year follow-up. After accounting for trajectory classes, the standard deviation of variation in 6MWD was reduced by approximately 40%. The natural history of ambulatory function in DMD may be composed of distinct trajectory classes. The extent to which trajectories are associated with novel and established prognostic factors warrants further study. Reducing unexplained variation in patient outcomes could help to further improve DMD clinical trial design and analysis.

摘要

杜氏肌营养不良症(DMD)患者6分钟步行距离(6MWD)随时间的变化差异很大,这使得治疗效果的临床试验变得复杂。我们评估了患有DMD的男孩是否可以被分为具有相似动态功能轨迹(通过6MWD测量)的类别。纳入了年龄在5岁及以上、经基因确诊患有DMD且在意大利11个护理中心参加自然史研究的能行走的男孩。对于每个男孩,在3年的时间里每年都有6MWD的标准化评估。使用潜在类别分析检查了6MWD与年龄的轨迹以及6MWD与入组时间的轨迹。总共纳入了96名男孩。入组时,平均年龄为8.3岁(平均6MWD:374米)。在考虑年龄、基线6MWD和类固醇使用情况后,确定了四个潜在轨迹类别,它们对3年6MWD结果的解释明显优于单一的平均轨迹。在3年随访期间,患者从入组开始的6MWD变化轨迹被分类为快速下降(n = 25)、中度下降(n = 19)、功能稳定(n = 37)和功能改善(n = 15)。在考虑轨迹类别后,6MWD变化的标准差降低了约40%。DMD能行走功能的自然史可能由不同的轨迹类别组成。轨迹与新的和已确定的预后因素相关的程度值得进一步研究。减少患者结果中无法解释的变异有助于进一步改进DMD临床试验的设计和分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a036/5026045/a09aeccc17d5/nmd3195-fig-0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a036/5026045/affe817f03f9/nmd3195-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a036/5026045/59b6eb8db67c/nmd3195-fig-0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a036/5026045/3a0197bbf983/nmd3195-fig-0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a036/5026045/a09aeccc17d5/nmd3195-fig-0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a036/5026045/affe817f03f9/nmd3195-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a036/5026045/59b6eb8db67c/nmd3195-fig-0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a036/5026045/3a0197bbf983/nmd3195-fig-0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a036/5026045/a09aeccc17d5/nmd3195-fig-0004.jpg

相似文献

1
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.对杜兴氏肌营养不良症患者通过6分钟步行距离测量的动态功能自然史轨迹进行分类。
Neuromuscul Disord. 2016 Sep;26(9):576-83. doi: 10.1016/j.nmd.2016.05.016. Epub 2016 May 27.
2
Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.杜氏肌营养不良症患者6分钟步行距离变化的个体化预测
PLoS One. 2016 Oct 13;11(10):e0164684. doi: 10.1371/journal.pone.0164684. eCollection 2016.
3
Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.每日使用皮质类固醇的杜氏肌营养不良症患者的 6 分钟步行距离测量的活动能力和疾病进展。
Neuromuscul Disord. 2013 Aug;23(8):618-23. doi: 10.1016/j.nmd.2013.05.006. Epub 2013 Jun 13.
4
The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.6 分钟步行试验和杜氏肌营养不良症的其他终点:来自一项多中心研究的 48 周纵向自然史观察。
Muscle Nerve. 2013 Sep;48(3):343-56. doi: 10.1002/mus.23902. Epub 2013 Jun 26.
5
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.依特醇治疗无义突变型杜氏肌营养不良症(ACT DMD)患者的疗效:一项多中心、随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2017 Sep 23;390(10101):1489-1498. doi: 10.1016/S0140-6736(17)31611-2. Epub 2017 Jul 17.
6
The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.6 分钟步行试验作为杜氏肌营养不良症的一种新的疗效评价指标。
Muscle Nerve. 2010 Apr;41(4):500-10. doi: 10.1002/mus.21544.
7
The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.6 分钟步行试验和其他杜氏肌营养不良症的临床终点:来自多中心研究的可靠性、相关性和最小临床重要差异。
Muscle Nerve. 2013 Sep;48(3):357-68. doi: 10.1002/mus.23905. Epub 2013 Jul 17.
8
Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids.参与drisapersen DMD114673研究的杜氏肌营养不良症受试者与每日服用皮质类固醇的匹配自然史队列受试者的活动能力和疾病进展比较。
Neuromuscul Disord. 2017 Mar;27(3):203-213. doi: 10.1016/j.nmd.2016.11.013. Epub 2016 Nov 25.
9
Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy.建模杜氏肌营养不良症男童早期异质性进展速度。
J Neuromuscul Dis. 2023;10(3):349-364. doi: 10.3233/JND-221527.
10
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles.五种多变量杜氏肌营养不良症进展模型,连接六分钟步行距离和腿部肌肉 MRI 弛豫率。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):671-683. doi: 10.1007/s10928-024-09910-1. Epub 2024 Apr 12.

引用本文的文献

1
Predicting trajectories of the north star ambulatory assessment total score in Duchenne muscular dystrophy.预测杜氏肌营养不良症中北极星动态评估总分的轨迹
PLoS One. 2025 Jun 27;20(6):e0325736. doi: 10.1371/journal.pone.0325736. eCollection 2025.
2
Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions.对杜氏肌营养不良症和相关病症的健康状态效用估计进行编目。
Health Qual Life Outcomes. 2024 Sep 2;22(1):72. doi: 10.1186/s12955-024-02287-2.
3
"If you cannot measure it, you cannot improve it". Outcome measures in Duchenne Muscular Dystrophy: current and future perspectives.

本文引用的文献

1
Joint modeling of repeated multivariate cognitive measures and competing risks of dementia and death: a latent process and latent class approach.重复多变量认知测量与痴呆和死亡竞争风险的联合建模:一种潜在过程和潜在类别方法。
Stat Med. 2016 Feb 10;35(3):382-98. doi: 10.1002/sim.6731. Epub 2015 Sep 16.
2
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test.糖皮质激素对杜氏肌营养不良非行走男孩/男性的益处:一项使用上肢功能测试的多中心纵向研究。
Neuromuscul Disord. 2015 Oct;25(10):749-53. doi: 10.1016/j.nmd.2015.07.009. Epub 2015 Jul 17.
3
“如果你无法衡量它,你就无法改进它”。杜氏肌营养不良症的结果指标:现状与未来展望。
Acta Neurol Belg. 2025 Feb;125(1):1-12. doi: 10.1007/s13760-024-02600-2. Epub 2024 Jul 31.
4
Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials.杜氏肌营养不良症丧失行走能力前后的功能轨迹及其对临床试验的影响。
PLoS One. 2024 Jun 3;19(6):e0304099. doi: 10.1371/journal.pone.0304099. eCollection 2024.
5
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.行业指南草案:杜氏肌营养不良症、贝克肌营养不良症和相关肌营养不良症——为整个疾病谱开发潜在的治疗方法。
J Neuromuscul Dis. 2024;11(2):499-523. doi: 10.3233/JND-230219.
6
Factors Associated with Respiratory Health and Function in Duchenne Muscular Dystrophy: A Systematic Review and Evidence Grading.与杜氏肌营养不良症患者呼吸健康和功能相关的因素:系统评价和证据分级。
J Neuromuscul Dis. 2024;11(1):25-57. doi: 10.3233/JND-230094.
7
Letter to the Editor: In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.致编辑的信:回应P.R. 克莱门斯等人的《维托拉森对杜氏肌营养不良症男孩的疗效和安全性:2期开放标签4年扩展研究结果以及维托拉森对杜氏肌营养不良症患者的长期功能疗效和安全性》。
J Neuromuscul Dis. 2023;10(6):1151-1153. doi: 10.3233/JND-239004.
8
Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy.建模杜氏肌营养不良症男童早期异质性进展速度。
J Neuromuscul Dis. 2023;10(3):349-364. doi: 10.3233/JND-221527.
9
Good response to the late treatment with ataluren in a boy with Duchenne muscular dystrophy: could the previous mild course of the disease have affected the outcome?对杜氏肌营养不良症男孩进行晚期阿托伦治疗的良好反应:之前疾病的轻度病程是否会影响治疗效果?
Acta Myol. 2022 Sep 30;41(3):121-125. doi: 10.36185/2532-1900-078. eCollection 2022.
10
Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives.基因治疗神经肌肉疾病:健康经济挑战与未来展望。
J Neuromuscul Dis. 2022;9(6):675-688. doi: 10.3233/JND-221540.
Ten-year blood pressure trajectories, cardiovascular mortality, and life years lost in 2 extinction cohorts: the Minnesota Business and Professional Men Study and the Zutphen Study.
两个队列研究中十年血压轨迹、心血管死亡率和生命年损失情况:明尼苏达商业与职业男性研究和祖特芬研究
J Am Heart Assoc. 2015 Mar 9;4(3):e001378. doi: 10.1161/JAHA.114.001378.
4
Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial.杜氏肌营养不良非行走患者一年随访期间上肢力量和功能变化:一项观察性多中心试验
PLoS One. 2015 Feb 2;10(2):e0113999. doi: 10.1371/journal.pone.0113999. eCollection 2015.
5
Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study.国际合作神经肌肉研究组杜氏肌营养不良自然史研究中步行能力的基因修饰因子
Ann Neurol. 2015 Apr;77(4):684-96. doi: 10.1002/ana.24370. Epub 2015 Mar 13.
6
Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing.临床前阿尔茨海默病的记忆衰退轨迹:澳大利亚影像、生物标志物和生活方式老龄化旗舰研究的结果
Neurobiol Aging. 2015 Mar;36(3):1231-8. doi: 10.1016/j.neurobiolaging.2014.12.015. Epub 2014 Dec 20.
7
Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants.杜氏肌营养不良症基因修饰因子的验证:一项评估SPP1和LTBP4变体的多中心研究。
J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1060-5. doi: 10.1136/jnnp-2014-308409. Epub 2014 Dec 4.
8
Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.进行性肌营养不良症行走期男孩的长期自然病史数据:36个月的变化
PLoS One. 2014 Oct 1;9(10):e108205. doi: 10.1371/journal.pone.0108205. eCollection 2014.
9
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.Drisapersen 治疗杜氏肌营养不良症(DEMAND II)的安全性和疗效:一项探索性、随机、安慰剂对照的 2 期研究。
Lancet Neurol. 2014 Oct;13(10):987-96. doi: 10.1016/S1474-4422(14)70195-4. Epub 2014 Sep 7.
10
Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study.杜氏肌营养不良男孩下肢骨骼肌的磁共振成像和波谱分析评估:一项多中心横断面研究
PLoS One. 2014 Sep 9;9(9):e106435. doi: 10.1371/journal.pone.0106435. eCollection 2014.